Low-Dose Naltrexone (LDN) and Gastrointestinal Health: Mechanisms, Clinical Evidence, and Integrative Applications A Comprehensive Academic Synthesis

An Academic Book Chapter

Yoon Hang "John" Kim, MD, MPH, FAAMA

Practice of Yoon Hang Kim, MD

San Antonio, TX 

www.directintegrativecare.com

Serving MO

May 2026

Copyright and Disclosures

© 2026 by the author. This chapter is intended for academic and educational use. The material may be reproduced for non-commercial educational purposes with appropriate attribution.

Disclosure of conflicts of interest: The author has no financial relationships with pharmaceutical manufacturers, supplement companies, or device manufacturers whose products are discussed in this chapter. The author maintains a clinical integrative medicine practice that includes gastrointestinal consultation; no payments have been received from any commercial interest for the content of this chapter.

Medical disclaimer: This chapter is intended for educational purposes and as an academic synthesis of contemporary literature on low-dose naltrexone and gastrointestinal disease. It does not constitute individual medical advice and is not a substitute for personalized clinical evaluation by a qualified gastroenterologist or integrative medicine physician. Patients with gastrointestinal disease should make all treatment decisions in partnership with their clinical team.

Funding: No external funding was received for the preparation of this chapter.

About the Author

Yoon Hang "John" Kim, MD, MPH, FAAMA, is a board-certified preventive medicine physician and integrative medicine specialist whose clinical and academic work has spanned functional medicine, acupuncture, mind–body medicine, and integrative approaches to autoimmune, gastrointestinal, and chronic inflammatory disease for more than two decades. He is a Fellow of the American Academy of Medical Acupuncture and has held faculty appointments at multiple academic medical centers. His current clinical practice (Practice of Yoon Hang Kim, MD; www.directintegrativecare.com) focuses on the application of evidence-informed complementary and functional medicine approaches to complex chronic illness, with particular emphasis on translating mechanism-based research into accessible patient care across telemedicine platforms. He has written extensively on low-dose naltrexone, SIBO, MCAS, mold illness, integrative oncology, and metabolic medicine.

Abstract

Background. Low-dose naltrexone (LDN), defined as daily doses of naltrexone in the range of 0.5–6 mg, exerts pharmacological properties qualitatively distinct from naltrexone at standard addiction-treatment doses (50–100 mg). At low doses, naltrexone functions as a Toll-like receptor 4 (TLR4) antagonist, a transient mu-opioid receptor blocker that upregulates endogenous opioid tone via compensatory rebound, and a modulator of the opioid growth factor (OGF)–OGF receptor (OGFr) axis. These mechanisms converge on anti-inflammatory, immunomodulatory, mucosal-healing, and prokinetic effects that are of direct relevance to gastrointestinal disease.

Objective. This chapter synthesizes the available basic science and clinical literature on LDN's gastrointestinal applications, with particular emphasis on Crohn's disease (CD), ulcerative colitis (UC), irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), intestinal permeability, and mast cell–mediated gastrointestinal dysfunction. Evidence tiers are distinguished explicitly throughout.

Structure. The chapter is organized into five parts. Part I covers mechanisms of action relevant to the gastrointestinal tract. Part II reviews clinical evidence in inflammatory bowel disease (IBD), including available randomized controlled trials, open-label studies, Cochrane data, and pharmacoepidemiological evidence. Part III reviews evidence for functional gastrointestinal disorders, SIBO, and intestinal permeability. Part IV addresses integrative clinical protocols, compounding specifications, dosing strategy, and patient selection. Part V addresses special considerations, drug interactions, safety monitoring, and future research directions.

Conclusion. LDN occupies a clinically meaningful and mechanistically credible position in the integrative gastroenterologist's toolkit. The strongest clinical evidence exists for Crohn's disease, where randomized controlled trial data support a clinically significant advantage over placebo for both clinical response and endoscopic remission. Evidence for ulcerative colitis, IBS, mesenteric panniculitis, systemic sclerosis–associated GI dysmotility, and SIBO is preliminary but consistently directionally positive. The drug's safety profile, low cost, and multi-target mechanism of action make it an attractive adjunctive option across a range of inflammatory and functional GI conditions.

Keywords: low-dose naltrexone, LDN, Crohn's disease, ulcerative colitis, inflammatory bowel disease, irritable bowel syndrome, SIBO, intestinal permeability, TLR4, opioid growth factor, mucosal healing, integrative gastroenterology, functional medicine

Learning Objectives

After completing this chapter, the reader will be able to:

1. Describe the three primary pharmacological mechanisms of LDN relevant to gastrointestinal tissue: TLR4 antagonism, opioid receptor rebound with endogenous opioid upregulation, and OGF–OGFr axis modulation.
2. Distinguish the evidence tier for LDN in Crohn's disease (randomized controlled trial data) from the evidence tier for functional GI disorders and SIBO (open-label, observational, and case-series data).
3. Summarize the primary findings of the Smith et al. (2007), Smith et al. (2011), and Smith et al. (2013) trial series from Penn State, including response rates, remission rates, endoscopic findings, and the pediatric safety data.
4. Interpret the Norwegian pharmacoepidemiological cohort data (Raknes et al., 2018) and explain what reductions in IBD medication dispensing following LDN initiation suggest—and do not suggest—about efficacy.
5. Describe LDN's mechanism as a prokinetic agent relevant to SIBO prevention and treatment, and identify populations in which LDN may serve as adjunctive prokinetic support.
6. Outline a rational, individualized LDN dosing and titration strategy for patients with inflammatory bowel disease and for patients with functional GI disorders or SIBO, including appropriate compounding specifications and formulation selection.
7. Identify the principal contraindications, drug interactions, and monitoring parameters relevant to LDN use in GI patients.
8. Apply a five-part clinical decision framework for selecting patients with GI disease who are candidates for adjunctive LDN therapy.

List of Abbreviations

Editorial Note: A Tiered-Evidence Approach

LDN literature is vulnerable to a specific form of epistemic conflation: the tendency to cite mechanism-based preclinical evidence, case reports, and randomized controlled trial data in adjacent paragraphs without signaling their profoundly different evidentiary weights. This chapter prevents that conflation through explicit evidence-tier labeling at the opening of each section:

• Part I: Mechanisms — Basic science: in vitro, preclinical, and human pharmacology.
• Part II: IBD Clinical Evidence — Randomized controlled trials, open-label prospective studies, Cochrane data, pharmacoepidemiological cohort studies.
• Part III: Functional GI, SIBO, and Intestinal Permeability — Open-label, observational, case-series, and expert clinical data.
• Part IV: Clinical Protocol — Expert consensus, clinical experience, and pharmacologic principles informed by the above evidence tiers.
• Part V: Special Considerations — Safety, drug interactions, monitoring, and future directions.

No section conflates these tiers. Evidence-tier headers appear explicitly where the quality of data requires orientation.

Part I: Mechanisms of Action Relevant to the Gastrointestinal Tract

Basic science: in vitro, preclinical, and human pharmacology.

1. The Pharmacological Paradox of Low-Dose Naltrexone

Evidence tier: Pharmacology, in vitro, and animal model data with human translational support.

Naltrexone, synthesized in 1963 and FDA-approved in 1984 at 50 mg daily for opioid and alcohol use disorder, exerts qualitatively distinct pharmacodynamics at doses approximately one-tenth of its standard therapeutic range. This departure from linear dose–response behavior has been described through the lens of hormesis—the phenomenon by which a substance produces opposing biological effects at high versus low doses—and has been confirmed across multiple independent laboratories.[^1][2]

At standard doses (50–100 mg), naltrexone produces sustained, essentially complete blockade of mu-, delta-, and kappa-opioid receptors. At low doses (0.5–6 mg), the blockade is transient, lasting approximately 4–6 hours, after which opioid receptor expression and endogenous opioid peptide production are upregulated during an 18–20 hour rebound window. These two time-distinct pharmacological phases—the transient blockade window and the subsequent opioid rebound—account for the majority of LDN's therapeutic effects. The clinical and preclinical evidence across conditions as diverse as Crohn's disease, fibromyalgia, multiple sclerosis, and SIBO can be traced, through distinct mechanistic pathways, to these two fundamental phases.[^3][2][^4][1]

2. TLR4 Antagonism: The Anti-Inflammatory Axis

Evidence tier: In vitro and animal model data; human translational inference.

The most extensively characterized non-opioid mechanism of LDN is antagonism of Toll-like receptor 4 (TLR4), a pattern recognition receptor expressed on macrophages, microglial cells, intestinal epithelial cells, and immune effector cells throughout the gastrointestinal mucosa. TLR4 is a central node in innate immune inflammatory signaling: its downstream cascades—mediated by MyD88 and TRIF adaptor proteins—drive synthesis of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, and interferon-β. In inflammatory bowel disease, TLR4 signaling is chronically upregulated in inflamed mucosa, perpetuating the cytokine milieu that drives epithelial injury and barrier dysfunction.[^2][5][^1]

LDN disrupts the TRIF portion of the TLR4 downstream cascade, reducing TNF-α and interferon-β synthesis. This anti-TLR4 activity is stereoselective in a manner that distinguishes it from classical opioid receptor pharmacology: while mu-opioid receptors selectively bind (−)-naltrexone isomers, TLR4 is not stereoselective and is blocked by both (−)- and (+)-naltrexone. This pharmacological feature has been exploited experimentally using (+)-naltrexone—a compound with no opioid receptor activity—to confirm that TLR4-mediated effects are independent of the endogenous opioid system.[^1][2]

In the gastrointestinal context, TLR4 antagonism by LDN has been shown in preclinical models to reduce expression of pro-inflammatory cytokines IL-6 and IL-12 in colonic cells, improve histological features of colitis, decrease systemic C-reactive protein and TNF-α levels, and reduce the severity of symptoms in rodent models of induced colitis. The clinical correlate—reduction in mucosal inflammation measurable on endoscopy—has been documented in open-label and randomized human trials discussed in Part II.[^2]

3. The OGF–OGFr Axis: Mucosal Healing and Cell Proliferation

Evidence tier: In vitro, preclinical, and mechanistic human data.

A mechanistically distinct pathway operates through the opioid growth factor (OGF), chemically identified as [Met5]-enkephalin, and its nuclear receptor OGFr. The OGF–OGFr axis is a constitutive, tonically active biological regulator of cell proliferation—functioning as a homeostatic brake on tissue growth, immune cell expansion, and cancer cell division under physiological conditions.[^4][6]

During LDN's transient 4–6 hour receptor blockade, OGFr becomes temporarily unoccupied by its endogenous ligand. This brief deprivation triggers compensatory upregulation of OGF production and OGFr expression at the translational (not transcriptional) level, mediated through p16 and p21 cyclin-dependent kinase inhibitory pathways. The subsequent 18–20 hour rebound window, during which both OGF and OGFr are elevated, produces a net tonic increase in the OGF–OGFr signaling axis that has documented effects on intestinal mucosal biology: enhanced epithelial cell migration and wound closure, suppression of pathological T-cell and B-cell proliferation relevant to autoimmune intestinal inflammation, and inhibition of tumor cell growth in colorectal, pancreatic, and ovarian cancer models.[^7][6][^4]

The translational significance for gastrointestinal disease is considerable. Intestinal mucosal healing—operationally defined in IBD as endoscopic remission, histologic normalization, or fistula closure—is increasingly recognized as a more meaningful clinical endpoint than symptom-based remission alone. LDN's documented capacity to enhance epithelial cell migration and reduce endoplasmic reticulum (ER) stress in intestinal organoid models provides a mechanistic basis for the mucosal healing observed in the clinical trial data reviewed in Part II.[^8][9][^2]

4. Endoplasmic Reticulum Stress Reduction in Intestinal Epithelial Cells

Evidence tier: In vitro data; adjunct to IBD clinical trials.

A third mechanistic pathway—operative at the intestinal epithelial cell level—involves LDN's capacity to reduce endoplasmic reticulum (ER) stress. ER stress is increasingly recognized as a central pathogenic mechanism in IBD, particularly in Crohn's disease, where abnormal protein folding and unfolded protein response (UPR) activation in intestinal epithelial cells amplify mucosal inflammation and impair barrier function.[^2]

In a series of in vitro experiments conducted alongside the Lie et al. (2018) clinical trial, naltrexone was shown to significantly reduce ER stress in intestinal tissue organoids exposed to bacteria and bacterial products including lipopolysaccharide (LPS). In a paired design using intestinal epithelial cells obtained from IBD patients before and after LDN treatment, ER stress markers were significantly reduced post-treatment. In scratch injury assays, naltrexone-treated colonic epithelial cell cultures (HCT116 and CACO2 lines) demonstrated markedly accelerated wound closure driven by enhanced cellular migration—a direct in vitro correlate of the mucosal healing observed clinically.[^8][2]

5. Prokinetic Mechanisms: Opioid Modulation of the Enteric Nervous System

Evidence tier: Pharmacological inference, preclinical data, clinical experience.

The gastrointestinal tract contains one of the highest densities of opioid receptors in the body, distributed across the enteric nervous system, smooth muscle, and epithelial layer. Endogenous opioid signaling through mu-opioid receptors in the enteric nervous system produces well-documented inhibitory effects on gastrointestinal motility—most clinically relevant in the context of opioid-induced constipation, but also pertinent to understanding basal motility regulation.[^10][11]

LDN's transient mu-opioid receptor blockade in the gastrointestinal tract produces a period of reduced opioid inhibition of enteric motility, followed by a rebound phase in which endogenous opioid signaling is upregulated. The net clinical effect, observed and reported in functional gastroenterology practice, is improvement in intestinal motility and migrating motor complex (MMC) function—the organized peristaltic contractions that sweep the small intestine during fasting and serve as the principal mechanism for preventing small intestinal bacterial overgrowth.[^12][11][^13]

This prokinetic mechanism distinguishes LDN from other anti-inflammatory agents used in IBD: while biologics and immunosuppressants address mucosal inflammation, they do not address the motility dysfunction that underlies SIBO, bacterial translocation, and the dysbiosis-driven perpetuation of intestinal inflammation. LDN's capacity to address both mucosal inflammation and intestinal motility simultaneously represents a mechanistic advantage in the integrated management of complex GI presentations.[^11][12]

Part II: Clinical Evidence in Inflammatory Bowel Disease

Randomized controlled trials, open-label prospective studies, Cochrane data, and pharmacoepidemiological cohort evidence.

6. Crohn's Disease: The Foundational Clinical Trial Series

Evidence tier: Open-label prospective pilot trial (Phase I/II); randomized placebo-controlled trial (Phase II); pediatric randomized pilot study.

The foundational clinical evidence for LDN in Crohn's disease emerges from a coherent series of investigator-initiated trials conducted by Jill P. Smith, MD, and colleagues at the Pennsylvania State University College of Medicine, Hershey, Pennsylvania, in collaboration with Ian S. Zagon, PhD, whose laboratory had established the OGF–OGFr axis as the mechanistic underpinning of LDN's cell-regulatory effects.[^14][15]

6.1 The 2007 Open-Label Pilot Trial (Smith et al., American Journal of Gastroenterology)

The first published human clinical trial of LDN in Crohn's disease enrolled 17 adult patients with histologically and endoscopically confirmed active disease, with Crohn's Disease Activity Index (CDAI) scores of 220–450. Oral naltrexone 4.5 mg was administered nightly for 12 weeks. The primary outcome was CDAI response and remission.[^16][14]

Results were striking for a pilot study of this design:

• 89% of patients exhibited a clinical response (≥70-point CDAI decrease).[^16]
• 67% achieved clinical remission (CDAI < 150), a statistically significant outcome (p < 0.001).[^14][16]
• CDAI scores decreased significantly from a mean of 356 ± 27 at baseline and remained lower than baseline at the 4-week post-treatment follow-up visit.[^14]
• Inflammatory bowel disease questionnaire (IBDQ) and Short Form-36 quality-of-life scores improved significantly with LDN compared to baseline.[^16]
• No laboratory abnormalities were noted; the most common adverse effect was sleep disturbances, occurring in 7 patients (41%).[^14]

This trial established proof of concept and safety for LDN in adult Crohn's disease and served as the basis for the subsequent randomized trial.[^17]

6.2 The 2011 Randomized Placebo-Controlled Trial (Smith et al., Digestive Diseases and Sciences)

The follow-up randomized, double-blind, placebo-controlled trial enrolled 40 patients with active Crohn's disease and represented the first controlled test of LDN's efficacy in IBD. Patients received either LDN 4.5 mg or placebo for 12 weeks, followed by 12 weeks of open-label naltrexone for all participants.[^18][10]

Key findings from the controlled phase:

• Clinical response was achieved in 88% of LDN-treated patients versus 40% of placebo patients.[^19][10]
• Endoscopic response was documented in 78% of LDN patients versus 28% of placebo patients—a finding that elevates the significance of the data beyond subjective symptom scoring.[^10]
• Histologic assessment of inflammation supported the endoscopic findings, with a significantly attenuated inflammatory infiltrate in the LDN group.[^19]
• Adverse effects were minimal and did not differ significantly from placebo.[^10]

The endoscopic remission signal in this trial is particularly important because it addresses the principal criticism of functional GI research: that subjective outcome measures are susceptible to placebo response and patient-expectation bias. Endoscopic and histologic improvement in a blinded controlled trial represents the strongest category of evidence available for a GI intervention outside of a large-scale phase 3 registration trial.[^10]

6.3 The 2013 Pediatric Pilot Study (Smith et al., Journal of Clinical Gastroenterology)

Recognizing the particular need for safe, non-immunosuppressive options in the pediatric Crohn's disease population—where growth retardation, nutritional compromise, and long-term immunosuppression carry compounded risks—Smith and colleagues conducted a dedicated pediatric safety and tolerability pilot trial.[^20][21][^22]

Fourteen children, mean age 12.3 years (range 8–17), with moderate to severe Crohn's disease (PCDAI ≥ 31) were enrolled. Children received naltrexone at 0.1 mg/kg orally for 8 weeks, followed by open-labeled treatment for an additional 8 weeks.

• PCDAI scores decreased significantly from pretreatment values of 34.2 ± 3.3 to 21.7 ± 3.9 after the 8-week course (p = 0.005).[^20]
• 25% of naltrexone-treated children achieved clinical remission (PCDAI ≤ 10).[^21][20]
• 67% had clinically meaningful improvement (decrease in PCDAI ≥ 10 points).[^20]
• Systemic and social quality of life improved significantly (p = 0.035).[^21]
• No serious adverse events were documented; the drug was well tolerated.[^20]

A separately published case report (Shannon et al., 2010) documented the first pediatric patient with duodenal Crohn's disease treated with LDN, whose symptoms improved at 4 weeks and who achieved complete mucosal healing with normal biopsies on repeat endoscopy 3 months after LDN initiation.[^23]

7. Inflammatory Bowel Disease: Beyond Crohn's Disease

Evidence tier: Open-label prospective studies, case reports, quasi-experimental pharmacoepidemiological cohort data.

7.1 The Lie et al. (2018) Open-Label IBD Trial

The most comprehensive single study addressing LDN across both Crohn's disease and ulcerative colitis is a prospective open-label trial reported by Lie and colleagues. A total of 47 patients with therapy-refractory active IBD—28 with Crohn's disease and 19 with ulcerative colitis—received LDN 4.5 mg daily in addition to standard treatment.[^2]

• 74.5% of patients experienced clinical improvement, defined as a decrease in disease activity lasting at least one month.[^19][2]
• 25.5% achieved clinical remission.[^19]
• Six patients achieved complete endoscopic remission, including five with mucosal healing.[^2]
• Adjunct in vitro studies from the same trial group confirmed that naltrexone reduced ER stress in intestinal organoids and accelerated wound healing in colonic epithelial scratch assays.[^2]

This trial is important because it included a robust UC cohort—a population for which controlled LDN trial data remain absent—and because the accompanying mechanistic studies established a credible cellular basis for the clinical observations. The adverse effect profile was favorable; four patients reported vivid dreams, which resolved with morning (rather than bedtime) dosing.[^2]

7.2 Ulcerative Colitis: Case Evidence

Case evidence for LDN in UC includes a report by Kais (2013) describing an 18-year-old female with active UC intolerant to mesalamine therapy who achieved dramatic improvement within one month of LDN initiation—resulting in 1–2 formed, non-bloody bowel movements daily and complete resolution of symptoms. This case is significant both for the rapidity of response and for the clinical context: the patient had declined biologics and immunomodulators, and LDN represented the only active pharmacological intervention. A 2022 case series by Weinstock described two patients with symptomatic Crohn's colitis and ileitis who achieved rapid clinical and endoscopic response to LDN initiated at 1 mg and increased to 4–4.5 mg daily.[^24][25]

Patients with UC in the CureTogether crowdsourced symptom database rated LDN as nearly as effective as infliximab (Remicade)—a remarkable patient-reported signal, acknowledged to carry methodological limitations but noteworthy as a real-world effectiveness observation.[^10]

7.3 The Norwegian Pharmacoepidemiological Cohort (Raknes et al., 2018)

The most population-level evidence bearing on LDN's real-world impact in IBD comes from a quasi-experimental before-and-after prescription database study conducted across the entire Norwegian population using the Norwegian Prescription Database (NorPD).[^26][10]

Following a sudden increase in LDN prescribing in Norway in 2013 (precipitated by a widely viewed television documentary), Raknes and colleagues identified 582 IBD patients who had received at least one LDN prescription and compared their dispensing of IBD medications during the two years before and two years after LDN initiation.[^10]

Among persistent LDN users (four or more prescriptions), the following reductions in IBD medication dispensing were observed relative to baseline—and in contrast to increasing use of the same drugs in the general Norwegian population over the same period:[^10]

These reductions were dose-dependent: they were most pronounced in the group with the greatest LDN exposure and were directionally absent or inverted in the group receiving LDN only once. The authors appropriately acknowledge the limitations of pharmacoepidemiological inference—drug dispensing is a proxy, not a direct measure of clinical benefit—but conclude that the findings reinforce the need for controlled efficacy trials and suggest clinically meaningful steroid-sparing effects.[^10]

7.4 Cochrane Systematic Review

The Cochrane Collaboration has reviewed LDN for induction of remission in Crohn's disease, with the review originally published in 2014 and updated in 2018. The 2018 update (Parker et al.) identified two eligible randomized controlled trials encompassing 46 participants (34 adults, 12 pediatric).[^27][28]

Meta-analysis demonstrated:[^27]

• A significant 70-point decrease in CDAI score in 83% of adult LDN patients (risk ratio 2.22; 95% CI 1.14–4.32).
• Endoscopic response was more common in LDN-treated patients (risk ratio 2.89; 95% CI 1.18–7.08).
• No statistically significant between-group difference in clinical remission by CDAI criteria, a finding attributed to insufficient power given the small combined sample size rather than a null effect.
• In the pediatric trial, 25% of LDN-treated children achieved PCDAI remission compared to 0% on placebo.
• The drug was well tolerated; adverse effects including sleep disturbances, fatigue, nausea, and headache occurred no more frequently in the LDN group than placebo.

The Cochrane reviewers rated the overall quality of evidence as low, reflecting the small sample sizes and risk of bias in the available trials—a judgment that accurately characterizes the current state of the literature rather than the magnitude of the observed effects.[^27]

7.5 Mesenteric Panniculitis

A small but relevant open-label trial (Melitas et al., 2015) tested LDN at 4.5 mg nightly for 12 weeks in three patients with symptomatic mesenteric panniculitis—an uncommon inflammatory condition of mesenteric adipose tissue that is refractory to most standard therapies. Two of three patients had symptomatic improvement. The drug was safe and well tolerated. While the sample size precludes conclusions, the case illustrates LDN's potential utility across diverse intra-abdominal inflammatory conditions.[^24]

Part III: Functional GI Disorders, SIBO, and Intestinal Permeability

Open-label pilot studies, observational data, expert clinical experience, and mechanistic inference.

8. Irritable Bowel Syndrome

Evidence tier: Open-label pilot study; no randomized controlled trial data available for IBS specifically.

The earliest published application of LDN to any gastrointestinal condition was not IBD but IBS. Kariv and colleagues (2006), from an Israeli research group, published a pilot open-label study enrolling 42 patients with IBS who received 0.5 mg LDN (marketed as PTI-901) daily for 4 weeks.[^29][30][^31]

Primary outcomes were pain-free days and a global assessment score:

• 76% of patients reported global improvement.[^30][29]
• The mean weekly number of pain-free days increased significantly from 0.5 ± 1 at baseline to 1.25 ± 2.14 during treatment (p = 0.011).[^29]
• No significant adverse reactions were observed.[^30]

The study authors concluded that LDN improved pain and overall well-being and was well tolerated, and recommended a large randomized double-blind placebo-controlled trial—a recommendation that has not yet been fulfilled as of the writing of this chapter. The dose used in this study (0.5 mg) is noteworthy because it is at the very low end of the LDN range, approximating what is now termed "very-low-dose naltrexone" (VLDN), and was used in the specific formulation PTI-901 designed to block excitatory opioid receptors preferentially while sparing inhibitory opioid receptor function.[^29][30]

A 2018 review from Dartmouth-Hitchcock Medical Center (Toljan and Vrooman, Medical Sciences) specifically cited IBS among the GI conditions for which LDN may be beneficial, reporting observational data from a retrospective clinical series in which a subset of GI patients experienced improvement in diarrhea, constipation, and pain. The Ploesser et al. (2010) case series also documented LDN efficacy in a range of GI disorders using condition-specific dosing (2.5 mg daily for diarrhea-predominant IBS; 2.5 mg twice daily for constipation-predominant IBS; 4.5 mg for IBD), with most patients experiencing helpful-to-marked improvement.[^32][1][^24]

9. Small Intestinal Bacterial Overgrowth (SIBO)

Evidence tier: Mechanistic inference, expert clinical experience, preclinical analogy; no randomized controlled trial data available.

SIBO—defined by bacterial colonization of the small intestine in excess of 10³ colony-forming units per milliliter in the proximal jejunum, or by a positive lactulose or glucose breath test—is pathophysiologically linked to impaired small intestinal motility, specifically failure of the migrating motor complex (MMC) phase III contractions that serve as the intestinal "housekeeper," clearing luminal bacteria between meals.[^12][11]

LDN's relevance to SIBO rests on three intersecting mechanisms:[^33][11][^12]

1. Prokinetic modulation via enteric opioid receptor blockade: By transiently blocking mu-opioid receptors in the enteric nervous system, LDN reduces opioid-mediated inhibition of intestinal motility and may enhance MMC amplitude and frequency during the post-blockade period. This effect positions LDN as a pharmacologically distinct prokinetic agent compared to serotonin agonists (prucalopride) or motilin agonists (low-dose erythromycin).[^13]
2. Anti-inflammatory support for a permeable, inflamed mucosa: SIBO perpetuates intestinal inflammation via LPS-mediated TLR4 signaling, tight junction disruption, and immune activation in the lamina propria. LDN's TLR4 antagonism directly interrupts this inflammatory amplification loop.[^34][11]
3. Immune modulation reducing SIBO-associated immune dysregulation: OGF-mediated modulation of T- and B-cell activity may attenuate the immune hyperactivation that characterizes SIBO-associated conditions including fibromyalgia, chronic fatigue, and MCAS—comorbidities that frequently co-occur with SIBO in integrative clinical practice.[^11][12]

In a SIBO-specific case series reported by Dr. Michael Arata and the SIBO community, LDN 2.5 mg daily was used for diarrhea-predominant SIBO and LDN 2.5 mg twice daily for constipation-predominant SIBO, with the following outcomes: improvement (mild to marked) in 68%, no response in 27%, and worsening in 5%. These figures are consistent with the overall pattern of LDN response data across GI conditions and are clinically plausible given the prokinetic and anti-inflammatory mechanisms described above.[^12]

An important caveat emphasized by SIBO expert clinicians is that LDN is often insufficient as a sole prokinetic agent for severe or recalcitrant SIBO, particularly in patients with underlying structural dysmotility disorders such as Ehlers-Danlos syndrome or systemic scleroderma, where LDN should be combined with a stronger pharmaceutical prokinetic (prucalopride, low-dose erythromycin) rather than used in isolation. This caveat aligns with the general principle that LDN functions optimally as an adjunctive agent rather than monotherapy in complex GI presentations.[^13]

10. Intestinal Permeability and "Leaky Gut"

Evidence tier: Preclinical data, mechanistic inference from IBD trials; no dedicated human permeability trials.

Increased intestinal permeability—characterized by disruption of tight junction proteins (zonulin, occludin, claudins) between intestinal epithelial cells, allowing translocation of luminal antigens, bacterial LPS, and other immune-activating molecules into the systemic circulation—is a recognized mechanism linking dysbiosis, chronic inflammation, and systemic autoimmunity.[^35][34]

LDN addresses intestinal permeability through multiple mechanisms:[^36][34]

1. Tight junction stabilization via TLR4 antagonism: LPS-mediated TLR4 activation in intestinal epithelial cells is a primary driver of tight junction protein degradation. LDN's TLR4 antagonism interrupts this pathway, providing a mechanistic basis for barrier protection.[^34]
2. Direct mucosal wound healing: As reviewed in the OGF–OGFr mechanism section, naltrexone accelerates epithelial cell migration and wound closure in intestinal scratch assays, suggesting a direct tissue-reparative effect on the mucosal barrier.[^36][8]
3. ER stress reduction: Chronic ER stress disrupts tight junction assembly in intestinal epithelial cells. LDN's demonstrated capacity to reduce ER stress in intestinal organoids may therefore support tight junction integrity through an indirect pathway distinct from the TLR4 and OGF mechanisms.[^36][2]
4. Endorphin-mediated immune modulation: Elevated beta-endorphin during the opioid rebound phase downregulates pro-inflammatory cytokines and modulates mast cell and T-cell activation—cellular populations that are primary drivers of tight junction disruption in immune-mediated intestinal disease.[^34][36]

In clinical practice, several integrative physicians—including practitioners at Renaissance Health Centre and other functional medicine practices—have incorporated LDN as an adjunctive component of leaky gut protocols alongside L-glutamine, zinc carnosine, colostrum, and targeted probiotic therapy, specifically to modulate immune-driven permeability in patients with MCAS, SIBO, or autoimmune disease.[^37]

11. Systemic Sclerosis–Associated Gastrointestinal Dysmotility

Evidence tier: Prospective case series (level 4 evidence).

Frech and colleagues (2011) reported a prospective case series of patients with systemic sclerosis–associated pruritus treated with LDN, in which gastrointestinal symptoms were systematically assessed using the validated University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) instrument. All patients demonstrated improvement in total GIT scores, with specific improvements in constipation and distention/bloating subscales. This is the only published prospective data using a validated instrument to characterize LDN's effects on GI symptoms in a systemic connective tissue disease—and it is positive, though the sample size is small and uncontrolled.[^24]

Part IV: Integrative Clinical Protocol for LDN in GI Disease

Expert consensus, clinical experience, and pharmacologic principles.

12. Patient Selection Framework

Evidence tier: Expert clinical protocol informed by above evidence tiers.

The following five-part framework assists in identifying GI patients who are appropriate candidates for adjunctive LDN therapy:

1. Inflammatory activity: LDN is most likely to produce benefit in patients with evidence of active mucosal inflammation (elevated CRP, fecal calprotectin, or endoscopic disease activity) rather than purely functional or structural pathology. TLR4 antagonism requires an active inflammatory target.
2. Prior therapy history: Patients with Crohn's disease or UC who have demonstrated inadequate response or intolerance to conventional therapies (aminosalicylates, corticosteroids, immunomodulators) are the most evidence-supported candidates. LDN may function as a bridge therapy, a steroid-sparing agent, or an adjunct to biologics—though drug interaction considerations require attention (discussed in Part V).
3. Comorbid immune dysregulation: Patients with co-occurring MCAS, fibromyalgia, chronic fatigue, or other systemic inflammatory conditions are likely to demonstrate broad benefit from LDN's TLR4 and OGF mechanisms beyond GI-specific effects, making it a particularly valuable adjunct in complex multi-system presentations.[^38]
4. Sensitivity profile: Patients with MCAS, chemical sensitivity, or multiple medication intolerances require ultra-low starting doses (as low as 0.001 mg) and hypoallergenic compounding formulations. Standard titration protocols are contraindicated in this population.[^38]
5. Opioid use status: Current use of opioid analgesics is a relative contraindication. Even low-dose naltrexone can meaningfully attenuate opioid analgesia and may precipitate withdrawal in opioid-dependent patients. If LDN is considered in a patient using opioids, a washout period of sufficient duration should be completed; the clinical literature and compounding prescribers recommend stopping LDN at least 3–7 days prior to elective surgery requiring opioid analgesia.[^39][3]

13. Dosing and Titration for GI Conditions

Evidence tier: Expert clinical protocol.

IBD (Crohn's Disease and Ulcerative Colitis)

The dose used in all controlled clinical trials of LDN for Crohn's disease has been 4.5 mg nightly (or 0.1 mg/kg in the pediatric trial). This represents the primary evidence-supported dosing strategy for inflammatory bowel disease.[^21][16]

For initiation in a clinical practice context:

• Standard approach: Begin at 1.5 mg nightly. Increase by 1.5 mg increments every 1–2 weeks to a target of 4.5 mg nightly.
• Sensitive patients (MCAS, fibromyalgia, chemical sensitivity): Begin at 0.5 mg or lower, with increments of 0.5 mg every 5–7 days. In extreme sensitivity, initiation at 0.001–0.5 mg using liquid suspension allows drop-by-drop titration.
• Timing: Evening dosing (1–2 hours before bed) is conventional, timed to coincide with the nocturnal peak of endogenous opioid production (approximately 3–4 AM), maximizing the rebound effect. Patients experiencing sleep disruption may benefit from morning dosing.[^3][38]
• Trial duration: A minimum 8–12 week trial is required before assessing response in IBD, consistent with the trial durations in all published studies.[^3][16]

Functional GI Disorders and SIBO

For IBS and SIBO, available evidence (primarily the Kariv pilot study and Ploesser case series) supports lower dosing:

• IBS: 0.5 mg daily (the dose validated in the Kariv pilot study).[^29]
• SIBO–diarrhea predominant: 2.5 mg daily.[^12]
• SIBO–constipation predominant: 2.5 mg twice daily.[^12]
• Titration from lower starting doses (0.5–1 mg) is advisable in patients with IBS-hypersensitivity phenotype or in those with MCAS overlap.

14. Compounding Specifications

Evidence tier: Pharmacological and clinical experience.

Commercially available naltrexone is supplied only as a 50 mg tablet—a dose roughly ten times higher than the upper end of the LDN therapeutic range. All clinical LDN use therefore requires compounding pharmacy preparation. Key compounding specifications for GI patients include:[^40][39][^38]

The clinical importance of hypoallergenic formulations in sensitive patients cannot be overstated: adverse reactions to excipients in standard compounded capsules are routinely mistaken for naltrexone intolerance, causing unnecessary discontinuation in patients who would have tolerated a hypoallergenic preparation.[^38]

Part V: Special Considerations, Safety, and Future Directions

15. Safety Profile

Evidence tier: Clinical trial adverse effect data across all published LDN studies.

LDN has one of the most favorable safety profiles of any pharmacological agent used in integrative medicine. Across the combined clinical literature encompassing randomized trials, open-label studies, and long-term retrospective series, no serious adverse events attributable to LDN have been reported.[^1][2]

Common adverse effects:

Hepatic safety: Even at standard doses (50 mg), naltrexone does not significantly alter hepatic enzyme activity. No hepatic toxicity has been reported at LDN doses.[^1]

Thyroid sensitivity: Increased thyroid hormone sensitivity has been reported in a subset of patients; thyroid medication dosage adjustment may be required.[^39]

16. Drug Interactions

Evidence tier: Pharmacological inference; no formal drug interaction studies at LDN doses.

17. Monitoring Parameters

For patients with IBD on LDN, minimum monitoring should include:

• Clinical disease activity assessment (CDAI, Harvey-Bradshaw, or physician global assessment) at baseline, 6 weeks, and 12 weeks.
• Fecal calprotectin and CRP at baseline and 12 weeks to document objective inflammatory response.
• Endoscopic reassessment at 12 weeks for patients with documented active endoscopic disease at baseline—consistent with the trial designs that produced the available evidence.
• Quality-of-life assessment (IBDQ, SF-36) to capture the multi-domain benefits documented in the clinical trials.
• Thyroid function (TSH, free T4) at baseline and 12 weeks in patients on thyroid hormone replacement.

18. Future Research Directions

Evidence tier: Research agenda.

The principal gaps in the LDN–gastrointestinal evidence base as of 2026 include:

1. The LDN Crohn Study (EudraCT2019-000852-32; NL9259): A randomized, double-blind, placebo-controlled multicenter trial conducted at Erasmus MC, Rotterdam, enrolling patients with mild-to-moderate Crohn's disease to receive LDN 4.5 mg daily or placebo for 12 weeks. The primary outcome is endoscopic remission at week 12 (SES-CD ≤ 2). This trial, designed with 85% power and 61 patients per arm, represents the most rigorously designed LDN–CD trial to date and its results are awaited as the definitive test of LDN's mucosal healing potential in an adequately powered sample.[^41]
2. Ulcerative colitis randomized trials: No placebo-controlled trial of LDN in UC has been completed; this represents the largest evidence gap in the IBD–LDN literature given the pharmacological rationale and positive observational signals.
3. SIBO–LDN interaction studies: A randomized trial examining LDN as an adjunctive prokinetic in SIBO management—addressing recurrence rate, breath test normalization, and quality of life—would provide the controlled evidence needed to support the clinical experience reported in integrative gastroenterology practice.
4. Biomarker-driven patient selection: Identification of baseline predictors of LDN response in GI patients—analogous to the ESR–LDN response correlation observed in fibromyalgia by Younger et al.—would enable precision selection of candidates most likely to benefit.[^1]
5. Microbiome interactions: Whether LDN's anti-inflammatory and prokinetic effects alter gut microbial composition in a directionally favorable manner—increasing microbial diversity, reducing pathobionts, or favoring short-chain fatty acid producers—is a mechanistically important and clinically relevant question that remains uninvestigated in controlled studies.

Conclusion

Low-dose naltrexone has moved from an orphan off-label curiosity to a mechanistically well-characterized, clinically meaningful adjunctive tool in integrative gastroenterology. Its multi-target mechanism—TLR4 antagonism producing anti-inflammatory cytokine suppression, OGF–OGFr upregulation producing mucosal healing and immune modulation, ER stress reduction supporting epithelial barrier integrity, and enteric opioid receptor modulation producing prokinetic effects—represents a pharmacological convergence on gastrointestinal pathophysiology that no single conventional agent replicates.[^4][1][^2]

The clinical evidence in Crohn's disease is the most robust: randomized controlled trial data consistently demonstrate clinical response rates of 83–89% and endoscopic response rates of 78% with LDN 4.5 mg, a profile that favorably compares to aminosalicylates and approaches early-generation immunomodulators in a disease context where one-third of patients are refractory to or intolerant of conventional therapies. The Norwegian pharmacoepidemiological data independently support a steroid-sparing and IBD medication–reducing effect in persistent LDN users at the population level. Pediatric safety data are reassuring.[^16][20][^2][10]

The evidence for functional GI conditions—IBS, SIBO, intestinal permeability—remains preliminary but mechanistically credible and directionally consistent. The gap between clinical observation and controlled trial evidence in these conditions is not explained by pharmacological implausibility but by the structural barriers—primarily the absence of patent protection and commercial development incentive for a generic off-patent compound—that have historically limited rigorous investigation of LDN across all its potential applications.[^1]

For the integrative gastroenterologist and functional medicine clinician, LDN represents a low-cost, low-risk, multi-mechanistic adjunct that fills a genuine therapeutic niche: patients with active IBD refractory or intolerant to conventional therapy, patients with functional GI disorders where inflammatory and motility mechanisms converge, and patients with complex multi-system presentations involving MCAS, SIBO, and intestinal permeability who benefit from a single agent capable of addressing multiple concurrent pathophysiological processes simultaneously. The responsible clinical posture is neither dismissal nor uncritical enthusiasm: it is to apply LDN within an evidence-tiered framework, to document responses rigorously, to contribute case data to the emerging literature, and to advocate for the controlled trials that this underinvestigated compound deserves.

References

1. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory ... - Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fib...
2. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization - PMC - Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial i...
3. [PDF] Low Dose Naltrexone - Bateman Horne Center - Naltrexone is more commonly known for its indication in addiction medicine, given at 50 – 100 mg per...
4. Low-dose naltrexone (LDN): Tricking the body to heal itself - Zagon and McLaughlin not only discovered the phenomenon of LDN, and subsequently the OGF-OGFr axis, ...
5. Inflammatory Bowel Disease: Background, Pathophysiology, Etiology - Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response t...
6. Low-dose naltrexone targets the opioid growth factor-opioid growth ... - Naltrexone (NTX) is an opioid antagonist that inhibits or accelerates cell proliferation in vivo whe...
7. The opioid growth factor (OGF) and low dose naltrexone (LDN ... - We now show that both OGF and LDN have a marked effect on suppressing the progression of human ovari...
8. Low Dose Naltrexone Reduces In Vitro Endoplasmic Reticulum ... - It may have a beneficial effect in the treatment of IBD by directly stiumulating epithelial wound he...
9. Overcoming the challenges of overtreating and undertreating ... - This Review details the importance of adopting clinical strategies to avoid the pitfalls of undertre...
10. The Effect of Low-Dose Naltrexone on Medication in Inflammatory ... - Low-dose naltrexone [LDN] is a controversial off-label treatment used by many Crohn’s disease [CD] a...
11. LDN and SIBO - Haldey Compounding Pharmacy - As an opioid blocker, Naltrexone prevents opioids from attaching to your receptors and producing thi...
12. Low Dose Naltrexone (LDN) and Small Intestinal Bacterial Overgrowth (SIBO)
13. Prokinetics, LDN, and SIBO - SIBOINFO - Explore how prokinetics and Low-Dose Naltrexone (LDN) affect gut motility and SIBO. Learn about vari...
14. [PDF] Low-Dose Naltrexone Therapy Improves Active Crohn's Disease
15. [PDF] Low-Dose Naltrexone Therapy Improves Active Crohn's Disease - OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and ...
16. Low-dose naltrexone therapy improves active Crohn's disease - LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are ...
17. Gastro-Hep News - PMC
18. Use of naltrexone reduces inflammation in Crohn's patients ... - Naltrexone reduced inflammation in Crohn's patients in a new research study. Naltrexone is a drug us...
19. A Unique Option for Pain and Irritable Bowel Option Your Healthcare ... - LDN is a low cost option with few side effects which studies are showing to be effective in treating...
20. Safety and tolerability of low-dose naltrexone therapy in children ... - Naltrexone therapy seems safe with limited toxicity when given to children with Crohn's disease and ...
21. Safety and tolerability of low-dose naltrexone therapy in children ...
22. SAFETY AND TOLERABILITY OF LOW DOSE NALTREXONE ... - There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Rece...
23. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient - To the Editor:
24. Therapeutic Uses and Efficacy of Low-Dose Naltrexone - PMC - NIH - The clinical use of LDN remains off-label, with no standardized, regulatory-approved treatment proto...
25. P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative ... - Background. Low-dose naltrexone (LDN) has shown promise in several clinical studies as a safe and ef...
26. Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel ... - Our findings imply that the initiation of LDN in IBD is followed by reduced dispensing of several dr...
27. Low dose naltrexone for induction of remission in Crohn's disease - PubMed - Currently, there is insufficient evidence to allow any firm conclusions regarding the efficacy and s...
28. LDN and Crohn's Disease - OBJECTIVES: The primary objective was to evaluate the efficacy and safety of low dose naltrexone for...
29. Low-dose naltreoxone for the treatment of irritable bowel syndrome - PTI-901 improves pain and overall feeling, and is well tolerated by IBS patients. A large, randomize...
30. Low-Dose Naltrexone for the treatment of irritable bowel syndrome - Pilot study of Low Dose Naltrexone (LDN) in patients with irritable bowel syndrome (IBS). Study foun...
31. Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome - PTI-901 improves pain and overall feeling, and is well tolerated by IBS patients, and a large, rando...
32. Should we eat gluten? - The Low Dose Naltrexone Charity - Fasano's research is that it suggests we can prevent or sometimes even halt autoimmunity and chronic...
33. Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial ... - Here's how it works: LDN temporarily blocks opioid receptors for about four to six hours. The body r...
34. LDN and the Leaky Gut Explained - The Low Dose Naltrexone Charity - Basically, with increased intestinal permeability, the junctions between the epithelial lining cells...
35. Intestinal Permeability and its Regulation by Zonulin - PMC - NIH - Our data demonstrate that in the intestinal epithelium, CXCR3 is expressed at the luminal level, is ...
36. Low Dose Naltrexone (LDN) | Specialty Pharmacy in White Plains, NY - Gastrointestinal ↓. Naltrexone directly improves epithelial barrier function by improving wound heal...
37. Leaky Gut Treatment Las Vegas | Renaissance Health Centre - "Leaky gut" refers to the concept of increased intestinal permeability, where the intestinal lining ...
38. Low-Dose Naltrexone (LDN) Titration: Why "Start Low and Go Slow ... - LDN works through a mechanism often described as the “rebound effect”: by transiently blocking opioi...
39. Low Dose Naltrexone (LDN): Frequently Asked Questions (FAQs) - Commercially available naltrexone is only provided in a 50-mg tablet, but LDN therapy typically requ...
40. Low Dose Naltrexone (LDN) Therapy - Town & Country Compounding - Low Dose Naltrexone (LDN)Typically 0.5 to 4.5mg dose; Request Information ... Find the right LDN Dos...
41. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study - Introduction Crohn’s disease (CD) is an inflammatory bowel disease (IBD). Several drugs exist to ind...